Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin…

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. Cell Metabolism 2015

Document identifier
CEI-BR-065
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P
Title
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Source
Cell Metabolism
Year
2015
Volume, issue, pages
21(3):443–454
Digital object identifier
10.1016/j.cmet.2015.02.009
PubMed identifier
25738459
Record type
Journal article
Institute identifier
CEI-BR-065

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: MOTS-cCompound monograph
Monograph: NAD+ (nicotinamide adenine dinucleotide)Compound monograph
Monograph: 5-amino-1MQCompound monograph
3 citing documents.

§1.3Subject tags

mots-c preclinical mitochondria

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.